Uberflip

uberflip.com

Uberflip is the world’s #1 Content Experience Platform (CEP). With tools to aggregate all your marketing content, they empower B2B marketing and sales teams to create personalized content experiences to engage accounts, nurture prospects, and convert leads, without the help of IT. It’s their mission to put control back in the hands of marketing teams to deliver high-converting experiences, that put the customer front and center.

C-Suite On Deck

Q&A with Randy Frisch, CMO at Uberflip

MEDIA 7 | September 26, 2019

Randy Frisch, CMO and Co-Founder at Uberflip has led the content experience movement, prompting marketers to think beyond content creation and focus on the experience. Randy also co-hosts the Conex Show, a weekly podcast featuring top marketers and their strategies and secrets to success. His talks empower marketers with the strategies they need to capture their audiences, prove their worth, and align their vision. MEDIA 7: If I were to say to a bunch of people who know you, ‘Give me three adjectives that best describe you’, what would I hear? RANDY FRISCH: Determined, passionate, caring. M7: From Flipbooks to the world’s first content experience platform in just 6 years. What are some of the top reasons that helped drive Uberflip to where it is now? RF: We started as a solution that would allow marketers to share content to readers whenever they wanted and on whichever devices. People still want to consume content whenever they want. Think of the way in which we consume video content on Netflix or music content on Spotify. We’ve been successful in large part because we’ve been able to create a product that marketers need, that make it easier for their buyers to become customers. But that hasn’t been enough. The differentiator for us is culture—the values we strive for as an organization (not just the work environment). I’ll share my 3 favourites here: ? H.U.S.T.L.E.: this one stands for Heart, Unique, Skill, Tech, Lean, Entrepreneurial. My co-founder, Yoav Schwartz, and I actually screen new hires for these traits. ? Valuable, Relevant & Consistent: this one comes from the initial definition of Content Marketing (“creating and distributing valuable, relevant and consistent content”) by Robert Rose and Joe Pullizzi at the Content Marketing Institute. It only makes sense that our teams and employees should expect to be valuable,

8th International Conference on Bio-Sensing Technology

Conference

Related News

MedTech

CELLCARTA EXPANDS ITS BIOMARKER CAPABILITIES FOR CLINICAL TRIALS BY ADDING OLINK TECHNOLOGY TO ITS GLOBAL SERVICES

CellCarta | September 01, 2021

CellCarta and Olink Proteomics AB announced today a strategic collaboration to offer Olink® Target 96 & Target 48 to pharmaceutical and biotech customers, advancing targeted protein biomarker quantification in clinical studies. CellCarta is a global leader in precision medicine and with more than 20 years of experience in mass spectrometry the company continues to invest in the field of proteomic biomarkers to better understand diseases and support therapeutic development ...

Cell and Gene Therapy

GRAPHITE BIO ENROLLS FIRST PATIENT IN PHASE 1/2 CLINICAL TRIAL OF GPH101 FOR SICKLE CELL DISEASE

Graphite Bio | November 26, 2021

Graphite Bio, Inc. a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced that the first patient has been enrolled in the company’s Phase 1/2 clinical trial of GPH101, an investigational gene-edited autologous hematopoietic stem cell therapy designed to directly correct the genetic mutation that causes sickle cell disease. The company expects to treat the first patient with GPH101 in th...

Medical

NOVAVAX SUBMITS REQUEST TO THE U.S. FDA FOR EMERGENCY USE AUTHORIZATION OF COVID-19 VACCINE

Novavax, Inc. | January 31, 2022

Novavax, Inc. a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has submitted a request to the U.S Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for NVX-CoV2373, its protein-based COVID-19 vaccine candidate for immunization of individuals 18 year of age and older against SARS-CoV-2. The request for EUA is based on the totality of pre-clinical, clinical and...

Cell and Gene Therapy, Industrial Impact

IMMUNOGEN ANNOUNCES MULTI-TARGET LICENSING AND OPTION DEAL WITH VERTEX

ImmunoGen, Inc. | March 02, 2023

On March 1, 2023, ImmunoGen, Inc., a leading firm specializing in antibody-drug conjugates (ADCs), announced a global, multi-target license and option agreement with Vertex Pharmaceuticals. The deal provides Vertex with the rights to use ImmunoGen's ADC technology to research and discover targeted conditioning agents to be used in gene editing. After each research period, Vertex will have the option to obtain an exclusive worldwide license to research, develop, and commercia...

MedTech